Findings

What do systematic reviews say?

2 questions · 3 findings · 1 reviews · Childhood Cancer

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 33.3%Moderate 2 · 66.7%High 0 · 0%

Dexrazoxane vs no cardioprotective intervention

Heart failure · children with cancer receiving anthracyclines

Dexrazoxane showed no clear difference in clinical heart failure Available‐case analysis compared with no cardioprotective intervention (low certainty).

1 finding from 1 review

Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines 2022 · Cochrane Headline outcomes only
RR 0.2 [0.01, 4.19]
3 studies · 885 participants
Low

Dexrazoxane vs no cardioprotective intervention or placebo

Clinical heart failure and subclinical myocardial dysfunction combined Comparable definitions; see Characteristics of included studies for exact definitions. Available‐case analysis · adults with cancer receiving anthracyclines

Dexrazoxane probably leads to lower clinical heart failure and subclinical myocardial dysfunction… compared with no cardioprotective intervention or placebo (moderate certainty).

2 findings from 1 review

Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines 2022 · Cochrane Headline outcomes only
RR 0.37 [0.24, 0.56]
3 studies · 417 participants
Moderate
Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines 2022 · Cochrane Headline outcomes only
RR 0.46 [0.33, 0.66]
2 studies · 534 participants
Moderate